Profound advancements in oncology drug development have expanded the treatment options available to patients, yet therapeutic resistance and relapse continue to limit the efficacy and duration of clinical benefit of such treatments. Cancer resistance continues to be one of the most daunting challenges facing patients, clinicians and researchers in oncology today. At ORIC, our resistance platform is focused on three areas:
We are currently enrolling three phase 1 studies, which include ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer. Do you qualify?
Our collaborative, open culture gives each of us the authority, responsibility and support to do cutting-edge work on therapies for treatment-resistant cancers.
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates
ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting